Amicus Therapeutics shares surge 30.49% after-hours after BioMarin agrees to $4.8 billion acquisition.

Amicus Therapeutics surged 30.49% in after-hours trading following the announcement that BioMarin Pharmaceutical agreed to acquire the company for $4.8 billion in an all-cash transaction at $14.50 per share, a 33% premium to Amicus’ last closing price. The deal, approved by both boards, expands BioMarin’s rare disease portfolio with Amicus’ therapies for Fabry and Pompe diseases and adds high-growth revenue streams. The transaction’s immediate cash premium and strategic value for shareholders directly drove the sharp after-hours price increase, as investors reacted to the premium offer and anticipated regulatory and shareholder approvals. Other news, such as patent litigation resolution and third-party legal investigations, were secondary to the acquisition’s material impact on valuation.